InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: ku post# 277140

Tuesday, 10/25/2016 1:00:01 AM

Tuesday, October 25, 2016 1:00:01 AM

Post# of 346366
A great consultant and architect that likely knows how to make the most out of PS Targeting and connect a bridge to Stemcentrx.

You honestly think that one of those "dozens of collaborators" were not "STEMCENTRX" ? I don't know, but maybe he is smarter than you could imagine and all the talk about just a consultant may be pure conjecture

We know for a fact that Abbvie was in this with Peregrine, according to court records and Abbvie and Peregrine had a deal pending and SK even make a special trip to try and save the deal

We know know that Abbvie buys Stemcentrx (where Garnick is involved... and Peter Thiel) for $10.2 Billion

Seems a bit too easy there but we will find out and of course, deep rooted cancer hospitals like Duke, MSK and mothership NCCN.... and BP's AstraZeneca, Merck, Roche and now all tied to PS Targeting..

Something about to burst it seems, eh?

We can't say its been boring... waiting... waiting... because all BP's must compete and some will poach employees just to get an advantage and some will do Fargo things and some just go out and slowly build stealthy positions.... and some do a complete mix and some just go out and eventually buy what they want.

I think it is easy to see Peregrine Pharmaceuticals will be merged or bought out.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News